Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct.
Products, services, technology
Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes programs in stress urinary incontinence (SUI) and solid tumors.
We at Versameb believe that our VERSagile platform will fully implement its enormous potential together with selected partners who share our enthusiasm to address unmet medical needs with optimized mRNA. Please contact us to find out more about partnering opportunities.